Anti-human CD20 (N) (4-6:2C) Mouse IgG
- Quantity / Tests
- 100µg
- Species / Antigen
- Synthetic peptide (CMQSGPKPLFRRMSS)
- Host
- Mouse
- Subclass / Clone
- IgG3/4-6H:2C
- Type
- Monoclonal
- Purification
- Protein A
- Regulatory Status
- RUO
Rituximab used for treatment of lymphoma is an antibody drug targeting CD20. It has been reported that the C-terminal region of CD20 undertakes a critical role in binding to rituximab and the association between C-terminal mutations and rituximab-resistance has been investigated. This antibody was developed as a new monoclonal antibody that recognizes the N-terminal region of CD20 molecule to detect comprehensive CD20 regardless of C-terminal mutations. It is expected to be useful for the detailed examination of CD20 molecules by adding this antibody to research CD20.
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.